Fludarabine: all 769 studies that test it
Page 6 of 8. Open to participants first (148), then studies with results posted, then the rest; newest registration first within each.
- PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated MalignanciesStatus unknownNCT03044743Phase 1/2
- The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell LymphomaStatus unknownNCT03016988Phase 2
- Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02960646Phase 1
- Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma MultiformeStatus unknownNCT02937844Phase 1
- CD19-redirected Autologous Cells (CAR-CD19 T Cells)Status unknownNCT02933775Phase 1
- Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)Active, not recruitingNCT02932956Phase 1
- Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AMLCompletedNCT02926586Phase 4
- Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATGCompletedNCT02916979Phase 1
- Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)CompletedNCT02905188Phase 1
- Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 StudyStatus unknownNCT02894645Phase 4
- Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell CarcinomaStatus unknownNCT02876978Phase 1
- Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic AnemiaCompletedNCT02845596Not applicable
- Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma MultiformeStatus unknownNCT02844062Phase 1
- HLA-Identical Sibling Donor Bone Marrow Transplantation for Individuals With Severe Sickle Cell Disease Using a Reduced Intensity Conditioning RegimenStatus unknownNCT02776202Phase 2
- NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/AdolescentsCompletedNCT02763475Phase 2
- Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For LymphomaWithdrawnNCT02724904Phase 1/2
- International Randomised Phase III Clinical Trial in Children With Acute Myeloid LeukaemiaActive, not recruitingNCT02724163Phase 3
- Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic MalignanciesWithdrawnNCT02718755Phase 2
- Allogeneic Stem Cell Transplantation for Children With CMLCompletedNCT02707393Phase 2/3
- Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)WithdrawnNCT02702960Phase 2
- Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/LymphomaStatus unknownNCT02685670Phase 1/2
- Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell DiseaseTerminatedNCT02678143Phase 1
- Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic SyndromeTerminatedNCT02676323Phase 1
- Allo HSCT Using RIC for Hematological DiseasesCompletedNCT02661035Phase 2
- A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid TumorsTerminatedNCT02653196Early Phase 1
- Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT02649764Phase 1
- Genomics-Based Target Therapy for Children With Relapsed or Refractory MalignancyStatus unknownNCT02638428Phase 2
- Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic LeukemiaActive, not recruitingNCT02629809Phase 2
- Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell LymphomaWithdrawnNCT02548468Phase 1
- Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation (BMT) in Patients With Multiple Sclerosis (MS)Status unknownNCT02529839Not applicable
- CD19-Specific T-cells in Treating Patients With Advanced Lymphoid MalignanciesCompletedNCT02529813Phase 1
- In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic MelanomaWithdrawnNCT02489266Phase 1
- Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings SarcomaCompletedNCT02472392Phase 1
- Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell MalignanciesStatus unknownNCT02456350Phase 1
- Allogeneic Stem Cell Transplantation for Patients With Multiple MyelomaWithdrawnNCT02447055Early Phase 1
- 3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMAWithdrawnNCT02439788Phase 1
- TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma PatientsCompletedNCT02414945Phase 1/2
- Epigenetic Reprogramming in Relapse AMLTerminatedNCT02412475Phase 1
- Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid CancerWithdrawnNCT02390739Phase 1/2
- HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIACompletedNCT02379520Phase 1
- Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid MalignanciesStatus unknownNCT02333838Phase 2
- Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell TransplantSuspendedNCT02333162Phase 1
- Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT)TerminatedNCT02310997Phase 2
- Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic MelanomaCompletedNCT02278887Phase 3
- Azacytidine Plus FLAG for Relapsed or Refractory AMLStatus unknownNCT02275663Phase 2
- Infusion of Allogeneic, 3rd Party CD19-specific T CellsWithdrawnNCT02274506Phase 1
- Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic SyndromeActive, not recruitingNCT02250937Phase 2
- Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic SyndromeCompletedNCT02212561Phase 1
- Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)WithdrawnNCT02194374Phase 1
- Intra-Osseous Co-Transplant of UCB and hMSCCompletedNCT02181478Early Phase 1
- Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor SourceCompletedNCT02167958Phase 1
- Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic LeukemiaActive, not recruitingNCT02153580Phase 1
- Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02129582Phase 1
- Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell TransplantCompletedNCT02083250Phase 1
- Hematopoietic Stem Cell Transplant for Sickle Cell DiseaseCompletedNCT02065596Phase 1
- CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell TransplantActive, not recruitingNCT02061800Phase 1/2
- AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine ChemotherapyStatus unknownNCT02024308Phase 4
- Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Children and AdolescentsStatus unknownNCT02014506Phase 1/2
- Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood TransplantationStatus unknownNCT01983761Phase 1/2
- iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and NeuroblastomaActive, not recruitingNCT01953900Phase 1
- Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With MelanomaCompletedNCT01883323Phase 2
- 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAINActive, not recruitingNCT01822652Phase 1
- NY-ESO-1 T Cells in OG CancerTerminatedNCT01795976Phase 2
- Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01787474Phase 1
- Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin LymphomasStatus unknownNCT01786018Phase 2
- Assessment of Efficacy and Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab Chemoimmunotherapy in Young Patients With Chronic Lymphocytic Leukemia.CompletedNCT01762202Phase 2
- Haploidentical Stem Cell Transplantation for Children With Acquired Severe Aplastic AnemiaStatus unknownNCT01759732Phase 2
- Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT01758328Phase 1
- Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT01701323Phase 1
- High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior TreatmentTerminatedNCT01679041Phase 2
- Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis CongenitaActive, not recruitingNCT01659606Phase 2
- Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic MalignanciesCompletedNCT01658319Phase 1
- CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)CompletedNCT01653717Phase 1
- Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune DeficienciesActive, not recruitingNCT01652092Not applicable
- Vorinostat Plus FND in Relapsed or Refractory Mantle Cell LymphomaTerminatedNCT01578343Phase 2
- HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid TumorsStatus unknownNCT01509300Phase 1/2
- 90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT01503242Phase 1
- Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-MatchTerminatedNCT01500161Phase 2
- ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid LeukemiaWithdrawnNCT01478074Phase 1
- Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell TransplantationStatus unknownNCT01472055Phase 2
- PRO#0118: Decitabine Plus Mini Flu-BuCompletedNCT01455506Phase 1
- Treatment of Relapsed or Refractory Acute Myeloblastic LeukemiaCompletedNCT01435343Phase 1/2
- Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic LeukaemiaStatus unknownNCT01423747Phase 3
- ALL-SCT BFM International- HSCT in Children and Adolescents With ALLStatus unknownNCT01423500Phase 3
- Intensified Rituimab Prephase Before FCR in Untreated B-CLLCompletedNCT01370772Phase 2
- A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly PatientsCompletedNCT01303887Phase 3
- Umbilical Cord Blood Transplant for Children With Lymphoid Hematological MalignanciesWithdrawnNCT01247688Not applicable
- Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With CancerTerminatedNCT01212887Phase 1
- Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AMLCompletedNCT01191957Phase 3
- Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)CompletedNCT01186640Phase 2
- Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 DeficiencyActive, not recruitingNCT01176006Phase 2
- Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic MalignanciesCompletedNCT01175785Phase 2
- Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic AnemiaStatus unknownNCT01145976Phase 3
- Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic AnemiaWithdrawnNCT01129323Not applicable
- International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic LeukemiaCompletedNCT01117441Phase 3
- Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Aplastic AnemiaCompletedNCT01105273Phase 1/2
- Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)CompletedNCT01088724Phase 4
- Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT01085617
- Hematopoietic Stem Cell Transplant for Fanconi AnemiaCompletedNCT01071239Phase 2
- Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid MalignanciesCompletedNCT01056614Phase 2